Skip to content
Companies

Beacon Biosignals

EEG analytics and home sleep tests for drug trials

Raised to date

$103.3M

of $103.3M offered across 1 Form D filing

Investors
43
Last filed
Apr 15, 2026

About

Beacon Biosignals is a neurotechnology company that applies machine learning to EEG (electroencephalography) data to measure brain activity for drug development and clinical care. Its platform collects, integrates, and analyzes neurophysiology data across Phase 1-4 clinical trials, and its FDA 510(k)-cleared wearable headband brings sleep-stage EEG recording out of the sleep lab and into patients' homes. The company reports more than 2 million hours of EEG analyzed, over 500,000 home sleep tests completed, and support for 40+ clinical trials. It was founded in 2019 by Jacob Donoghue and Jarrett Revels and is headquartered in Boston, Massachusetts.

Pairs an FDA-cleared at-home EEG wearable with AI analytics trained on what the company describes as the world's largest clinically validated neurophysiology dataset, letting sponsors capture multi-night, real-world brain data instead of single-night lab polysomnography.

Funding

  • EquityFiled Apr 15, 2026Form D
    $103.3M/ $103.3M

Product

Beacon Biosignals EEG platform

Clinical trial neurodiagnostics platform

A precision-medicine platform for collecting, integrating, and analyzing EEG data across the drug development lifecycle, from trial design through biomarker discovery and patient stratification.

  • AI/ML analysis of EEG recordings for biomarker discovery
  • Support across Phase 1-4 clinical trials
  • Patient stratification and endpoint measurement for CNS programs

Built for

Pharmaceutical and biotech sponsors running central nervous system clinical trials, plus sleep physicians, neurologists, and primary care providers ordering home sleep tests

People on file